Particularly, CPT1A response to ATRA is impaired in those individuals with higher metabolic risk (overweight-obesity and low HDL levels), providing additional evidences of its previously reported role as a metabolic risk predictive biomarker. Here, CPT1A is linked to obesity due to melanocortin 4 receptor deficiency.